COMP <GO>
PBM vs MCRB // NET PROFIT MARGIN
Psyence Biomedical Ltd. (NASDAQ) VS. Seres Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PBM 1
— MCRB 1
■ METRIC PARITY
LAST: $3.61 (+6.18%) • MKT CAP: $19.2M
net-margins
—
LAST: $1.95 (+8.94%) • MKT CAP: $19.6M
net-margins
68.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBM VS. MCRB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBM | MCRB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 4.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | 68.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 5/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.1 | 20.9 | +14.22 | PBM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $19.2M | $19.6M | -$397.9K | MCRB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBM REV | MCRB REV | PBM GROSS % | MCRB GROSS % | PBM FCF | MCRB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $789.0K | — | — | — | $865.0K |
| FY 2024 | — | $0 | — | — | — | -$149.0M |
| FY 2023 | — | $0 | — | — | — | -$117.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBM // BETA —
MCRB // BETA —